-
Press Release
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
-
Press Release
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
-
Story
Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond -
Press Release
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
-
Story
Full Circle: A Story of Growth, Purpose and Coming Home to Novartis -
Story
Bringing proteins together to take cancer apart -
Story
Breaking ground in Global Health -
Press Release
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
-
Story
What's next in Neuroscience drug discovery -
Press Release
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
-
Press Release
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
-
Press Release
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)